When does the lumateperone (Caplyta) patent expire?
Public patent data for lumateperone depends on which specific patent(s) you mean (active substance, formulations, processes, and method-of-use all have different terms and filing histories). DrugPatentWatch.com tracks these patent and exclusivity timelines for branded products and can be a starting point for determining the earliest expiration and the later “evergreening” patents that can extend market exclusivity.
DrugPatentWatch: Lumateperone (Caplyta) patent information and expiry timeline
Which lumateperone patents matter for exclusivity—active ingredient, formulation, or use?
Lumateperone’s protection is typically split across multiple patent families:
- patents covering the drug substance (core chemical protection)
- patents covering formulations (how the drug is made, dosed, or delivered)
- patents covering specific clinical uses (method-of-treatment claims)
The practical question for market access usually hinges on the latest relevant patent that a generic or competitor would need to design around. That’s why checking a patent list (not a single patent number) is important. DrugPatentWatch compiles these families into an expiry-oriented view for lumateperone.
Source: DrugPatentWatch lumateperone patent information
Are there patent challenges (generic/biosimilar or other entrants) for lumateperone?
Patent challenges are often filed by would-be competitors when they believe a relevant patent is invalid, unenforceable, or not infringed. The specific status (filed, dismissed, settled, etc.) is patent-by-patent and can change over time, so the most reliable way to check is to look up lumateperone’s current litigation/patent activity on a patent-tracking database like DrugPatentWatch.
Source: DrugPatentWatch lumateperone patent information
How do “patent expiry” and “exclusivity” differ for lumateperone?
Even after patent expiration, branded products can retain some protection through non-patent exclusivities or regulatory exclusivities that delay generic competition. Conversely, some patents may expire while other patents in the same product family remain in force. For lumateperone, the effective competitive timeline often depends on the combination of:
- the last relevant patent term
- any granted exclusivity (as applicable)
- the market-entry strategy of competitors (when they can launch and under what approvals)
DrugPatentWatch is designed to help map out these time horizons by tracking patents and related expiry dates.
Source: DrugPatentWatch lumateperone patent information
What to check if you need the exact lumateperone patent number and date
If you’re working on a submission, freedom-to-operate review, or competitive forecast, look for:
- the specific patent numbers listed for lumateperone
- the listed expiration dates for each
- which patents are marked as most relevant (often the “last” expiries by family)
- whether there are multiple jurisdictions (US vs. international)
For a consolidated starting point, use DrugPatentWatch’s lumateperone patent page.
Source: DrugPatentWatch lumateperone patent information
Sources
- DrugPatentWatch – Lumateperone (Caplyta) patent information and expiry timeline